BOX 50 WP-1644

Fulbright & Jaworski L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701

WRITER'S INTERNET ADDRESS: JHURT@FULBRIGHT.COM

TELEPHONE: 5

FACSIMILE: 512

WRITER'S DIRECT DIAL NUMBER: 512/418-5674

RECEIVED

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

JUL 0 9 2001

TECH CENTER 1600/2900

FILE: FBRC:004USC1

June 29, 2001

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 2023 of the date below:

June 29, 2001

Date

Steven L. Highlander

ATTN: BOX SEQUENCE Commissioner for Patents Washington, DC 20231

RE: U.S. Patent Application SN 09/576,101, Entitled "POLEPITOPE VACCINES" -

Suhrbier et al. - (Client's Ref. No 92728)

Sir:

Enclosed for filing in the above-referenced patent application is:

- 1. An Amendment and Response to Official Communication Dated May 30, 2001;
- 2. A Substitute Sequence Listing;
- 3. Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g);
- 4. Substitute computer-readable form (CRF) copy of the Sequence Listing, and a separate paper copy;
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and
- 6. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Commissioner for Patents June 29, 2001 Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Assistant Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10019437/01973.

Respectfully submitted,

Steven 1). Highlander

Reg. No. 37,642

SLH/cpj Encl.